Specialty Drugmaker Nevakar Rakes in $55 Million

Published: Jul 27, 2016

Nevakar Announces $55 Million Fundraising

BRIDGEWATER, N.J., July 27, 2016 /PRNewswire/ -- Nevakar LLC, a privately-held specialty pharmaceutical company developing innovative products focused on therapies within the injectable and ophthalmic space, today announced that it has raised $55 million. Proceeds from the financing will be used to continue to develop the company's product pipeline and for general corporate purposes.

"Completion of this offering is a key milestone achievement for Nevakar, as it allows us to accelerate the development of our product pipeline to address significant unmet clinical and commercial needs," said Navneet Puri, Ph.D., Founder and Chief Executive Officer of Nevakar. "Our product pipeline now contains multiple development programs that are expected to provide patient-centric benefits."

About Nevakar
Nevakar is a specialty pharmaceutical company focused on therapies within the injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently FDA-approved molecules, through intensive R&D and clinical efforts. Nevakar has a comprehensive infrastructure for product development at its New Jersey facilities. More information about Nevakar can be found at www.nevakar.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nevakar-announces-55-million-fundraising-300304525.html


Back to news